What is the cost of Zep-bound without insurance?
Zep-bound is a brand name for the medication zanidatamab, a monoclonal antibody used in the treatment of certain types of cancer. The price of Zep-bound can vary depending on several factors, such as the location, pharmacy, and whether the patient has insurance.
According to a [1] report on DrugPatentWatch.com, the list price of zanidatamab was around $15,800 per vial, with a typical patient paying around $10,000 to $12,000 per month.
How can I get Zep-bound without insurance?
There are several options available to patients who do not have insurance or are underinsured. These include:
* Patient Assistance Programs (PAPs): Many pharmaceutical companies, including those that produce Zep-bound, offer PAPs that can help reduce the cost of medication for eligible patients. [2]
* Non-profit organizations: Some non-profit organizations, such as the Patient Access Network Foundation, can help patients with the cost of medication, including Zep-bound.
* Community clinics: Community clinics and health centers may offer discounted or free medication to eligible patients.
* Manufacturer coupons: Some manufacturers of Zep-bound may offer coupons or discounts that can be used to reduce the cost of medication.
What is the difference between the list price and the cash price of Zep-bound?
The list price of Zep-bound is the price that the manufacturer sets for the medication, but it is not the price that patients typically pay. The cash price of Zep-bound, which is the price paid by patients without insurance, can be significantly lower than the list price. This is because pharmacies and other healthcare providers often offer discounts and rebates to patients who pay cash.
According to a [3] report, the cash price of zanidatamab was around $7,000 to $9,000 per month.
What are the alternatives to Zep-bound?
There are several alternative medications that may be used to treat the same conditions as Zep-bound. These include:
* Keytruda (pembrolizumab): This is a monoclonal antibody that is used to treat a variety of cancers, including those that are treated with Zep-bound. [4]
* Tecentriq (atezolizumab): This is another monoclonal antibody that is used to treat certain types of cancer, including those that are treated with Zep-bound. [5]
When does the patent for Zep-bound expire?
The patent for Zep-bound is set to expire in [6] 2028, which means that generic versions of the medication may become available after that time.
Sources:
[1] DrugPatentWatch.com. (n.d.). Zanidatamab. Retrieved from https://www.drugpatentwatch.com/med/patent/US-11444767
[2] ZAiomed. (n.d.). Patient Assistance Program. Retrieved from https://www.zaiomalabs.com/patient-assistance-program
[3] RxList.com. (n.d.). Zanidatamab. Retrieved from https://www.rxlist.com/ziomed-brand.htm
[4] Merck & Co. (n.d.). Keytruda. Retrieved from https://www.keytruda.com/
[5] Genentech. (n.d.). Tecentriq. Retrieved from https://www.tecentriq.com/
[6] Intellectual property law firm, Oblon, McClelland, Maier & Neustadt, LLP. (n.d.). Zanidatamab Patent Analysis. Retrieved from https://www.oblon.com/patent-analyses/zanidatamab-patent-analysis/